Infinitt North America, an award-winning developer of enterprise imaging solutions for healthcare, today announced a partnership to market Lunit AI software, making it readily available to its North American customer base.

January 13, 2022 — Infinitt North America, an award-winning developer of enterprise imaging solutions for healthcare, today announced a partnership to market Lunit AI software, making it readily available to its North American customer base. Lunit recently received FDA 510 (k) clearance for Lunit Insight MMG, for detecting breast cancer, and Lunit CXR Triage, a Chest X-ray solution developed for sorting and prioritizing emergency cases. 

By partnering with Lunit, Infinitt can offer an enhanced integration with the AI solutions, enabling radiologists and ER clinicians to apply the algorithms and machine learning seamlessly, without any disruption in workflow.

Developed using Lunit’s deep learning technology, Lunit Insight MMG accurately analyses mammography images to detect lesions that could indicate breast cancer and provides location information for any detected lesions in the form of outlines and heatmaps. The computer-assisted diagnostic software has shown excellent performance in the early detection of breast cancer.

Lunit Insight CXR Triage chest detection suite accurately detects pre-specified suspected critical findings in chest X-ray's (pleural effusion and/or pneumothorax), quickly identifying critical conditions needing immediate attention. The algorithm performs at a 98-99% accuracy rate. 

David Smarro, President and CEO of Infinitt North America, is pleased to be partnering with a leading AI developer, marketing solutions that have already received FDA clearance. 

“Artificial Intelligence has so much potential in imaging informatics, both as a diagnostic tool and in getting all relevant patient data to the right clinician or subspecialist as quickly as possible. Earlier and more accurate diagnosis, earlier treatment, and a more patient-centered approach to care will improve clinical outcomes and reduce healthcare costs,” said Smarro.

With Lunit Insight MMG, rapid triage of screening mammograms will filter out benign cases for later evaluation, helping to reduce strain on radiologists as 60% of screening mammograms come up normal. 

For more information: www.infinittna.com/

 

 


Related Content

News | MRI Breast

July 2, 2026 – Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool which ...

Time July 02, 2026
arrow
News | Women's Health

July 1, 2026 — Despite declining birth rates worldwide, the complexity of pregnancy is increasing. Advanced maternal age ...

Time July 01, 2026
arrow
News | Mammography

June 30, 2026 — The Food and Drug Administration has cleared new contrast-enhanced mammography (CEM) and CEM biopsy ...

Time June 30, 2026
arrow
News | Information Technology

June 26, 2026 — Radin Health recently announced the successful deployment of its cloud-native platform at four ...

Time June 26, 2026
arrow
News | FDA

June 25, 2026 — Aidoc recently announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device ...

Time June 25, 2026
arrow
News | Interventional Radiology

June 25, 2026 — Radiologists performing no interventional radiology-related (IR-related) work increased from one-third ...

Time June 25, 2026
arrow
News | Mammography

June 23, 2026 — Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer ...

Time June 24, 2026
arrow
News | Pediatric Imaging

June 16, 2026 — Crescom has officially launched a global clinical Proof of Concept (PoC) of its pediatric ...

Time June 24, 2026
arrow
News | Information Technology

June 24, 2026 — HOPPR Presto Agent (Presto) is now commercially available from HOPPR. Presto iis a tool that ntegrates ...

Time June 24, 2026
arrow
News | Digital Pathology

June 17, 2026 — Proscia has introduced the Fifth Generation of its Concentriq1 platform, helping pathologists focus on ...

Time June 22, 2026
arrow
Subscribe Now